Verona Pharma plc Verona Pharma To Announce Interim Results For Six Months Ended June 30, 2017 And Provide Clinical Developme...
03 August 2017 - 1:00AM
UK Regulatory
TIDMVRP
LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces today that it will report its
interim results for the six months ended June 30, 2017 on Tuesday,
August 8, 2017.
Verona Pharma will host an investment community conference call at 8:00
a.m. Eastern Daylight Time (1:00 pm British Summer Time) on August 8,
2017 to discuss the interim financial results and provide a clinical
development update.
Analysts and investors may participate in the conference call by
utilizing the conference ID: 4729485 and dialing the following numbers:
-- (877)280-2296 or (646)254-3367 for callers in the United States
-- 0800 279 4841 or 44(0)20 3427 1905 for callers in the United Kingdom
-- 0800 589 2674 or 49(0)69 2222 10624 for calls in Germany
Those interested in listening to the conference call live via the
internet may do so by visiting the "Investors" page of Verona Pharma's
website at www.veronapharma.com and clicking on the webcast link.
A webcast replay of the conference call [audio] will be available on the
"Investors" page of Verona Pharma's website at www.veronapharma.com.
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled,
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as
both a bronchodilator and an anti-inflammatory agent in a single
compound. Verona Pharma is developing RPL554 for the treatment of
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF),
and potentially asthma.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
N+1 Singer (Nominated Adviser and UK Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / James White / Alex
Laughton-Scott
FTI Consulting (UK Media and Investor Tel: +44 (0)20 3727 1000
enquiries)
Simon Conway / Stephanie Cuthbert / veronapharma@fticonsulting.com
Natalie Garland-Collins
ICR, Inc. (US Media and Investor enquiries)
James Heins Tel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
August 02, 2017 11:00 ET (15:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma News Articles